With Evidence of Progressive Disease on or Within 6 Months
Drug | Drug Name | Drug Description |
---|---|---|
DB05773 | Trastuzumab emtansine | An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB05773 | Trastuzumab emtansine | Receptor tyrosine-protein kinase erbB-2 | target |
DB05773 | Trastuzumab emtansine | P-glycoprotein 1 | transporter |
DB05773 | Trastuzumab emtansine | Cytochrome P450 3A4 | enzyme |
DB05773 | Trastuzumab emtansine | Cytochrome P450 3A5 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|